163 related articles for article (PubMed ID: 38196535)
1. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study.
Satoi S; Yamamoto T; Hashimoto D; Yamaki S; Matsui Y; Ikeura T; Boku S; Shibata N; Tsybulskyi D; Sekimoto M
J Gastrointest Oncol; 2023 Dec; 14(6):2587-2599. PubMed ID: 38196535
[TBL] [Abstract][Full Text] [Related]
2. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial.
van Dongen JC; Versteijne E; Bonsing BA; Mieog JSD; de Hingh IHJT; Festen S; Patijn GA; van Dam R; van der Harst E; Wijsman JH; Bosscha K; van der Kolk M; de Meijer VE; Liem MSL; Busch OR; Besselink MGH; van Tienhoven G; Groot Koerkamp B; van Eijck CHJ; Suker M;
Eur J Surg Oncol; 2023 Apr; 49(4):811-817. PubMed ID: 36585300
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
[TBL] [Abstract][Full Text] [Related]
4. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis.
Shimura M; Mizuma M; Hayashi H; Mori A; Tachibana T; Hata T; Iseki M; Takadate T; Ariake K; Maeda S; Ohtsuka H; Sakata N; Morikawa T; Nakagawa K; Naitoh T; Kamei T; Motoi F; Unno M
Surg Case Rep; 2017 Dec; 3(1):132. PubMed ID: 29285651
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
[TBL] [Abstract][Full Text] [Related]
6. Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study.
Jiang YJ; Zhou SC; Chen JH; Liang JW
Front Oncol; 2022; 12():951540. PubMed ID: 36330479
[TBL] [Abstract][Full Text] [Related]
7. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma.
Piper M; Ross RB; Hu J; Watanabe S; Knitz M; Mehrotra S; Shulick R; Chiaro MD; Karam SD
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):627-639. PubMed ID: 36599398
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
[No Abstract] [Full Text] [Related]
9. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
10. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma.
Kawahara K; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Clin Exp Metastasis; 2022 Apr; 39(2):311-322. PubMed ID: 35000025
[TBL] [Abstract][Full Text] [Related]
11. Objective Definition and Optimized Strategy for "Biologically Borderline Resectable" Colorectal Liver Metastases.
Takamoto T; Nara S; Ban D; Mizui T; Murase Y; Esaki M; Shimada K; Hashimoto T; Makuuchi M
World J Surg; 2023 Nov; 47(11):2834-2845. PubMed ID: 37540268
[TBL] [Abstract][Full Text] [Related]
12. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemotherapy.
Yee EJ; Torphy RJ; Thielen ON; Easwaran L; Franklin O; Sugawara T; Bartsch C; Garduno N; McCarter MM; Ahrendt SA; Schulick RD; Del Chiaro M
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38780693
[TBL] [Abstract][Full Text] [Related]
13. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
[TBL] [Abstract][Full Text] [Related]
14. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy.
Crippa S; Cirocchi R; Weiss MJ; Partelli S; Reni M; Wolfgang CL; Hackert T; Falconi M
Updates Surg; 2020 Mar; 72(1):39-45. PubMed ID: 31997233
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1).
Wei M; Shi S; Hua J; Xu J; Yu X;
BMJ Open; 2019 Dec; 9(12):e033452. PubMed ID: 31818843
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
19. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma.
Yasuda S; Nagai M; Terai T; Kohara Y; Sho M
Ann Gastroenterol Surg; 2023 May; 7(3):358-366. PubMed ID: 37152775
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature.
Sakaguchi T; Valente R; Tanaka K; Satoi S; Del Chiaro M
Pancreatology; 2019 Jul; 19(5):672-680. PubMed ID: 31285145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
